The KRAS gene is commonly mutated in human cancers, rendering the encoded small GTPase constitutively active and oncogenic. This gene has the unusual feature of being enriched for rare codons, which limit protein expression. Here, to determine the effect of the rare codon bias of the KRAS gene on de novo tumorigenesis, we introduced synonymous mutations that converted rare codons into common codons in exon 3 of the Kras gene in mice. Compared with control animals, mice with at least 1 copy of this Krasex3op allele had fewer tumors following carcinogen exposure, and this allele was mutated less often, with weaker oncogenic mutations in these tumors. This reduction in tumorigenesis was attributable to higher expression of the Krasex3op allele, which induced growth arrest when oncogenic and exhibited tumor-suppressive activity when not mutated. Together, our data indicate that the inherent rare codon bias of KRAS plays an integral role in tumorigenesis.
Authors
Nicole L.K. Pershing, Benjamin L. Lampson, Jason A. Belsky, Erin Kaltenbrun, David M. MacAlpine, Christopher M. Counter
(A) Strategy to generate Cdkn2a–/– and Cdkn2a+/+ littermates with Krasex3op/ex3op, Krasex3op/nat, and Krasnat/nat genotypes for urethane carcinogenesis. (B) Similar tumor burden (P = 0.69), (C) number (P = 0.49), and (D) size (P = 0.23) between Kras genotypes (mean ± SEM) in the context of a Cdkn2a–/– background, as assessed 2.5–3 months after urethane administration (n ≥13). P values were calculated by 1-way ANOVA with Bonferroni’s multiple comparisons test.